Chemical Synthesis Elucidates the Key Antigenic Epitope of the Autism-related Bacterium Clostridium bolteae Capsular Octadecasaccharide
»
Chemical Synthesis Elucidates the Key Antigenic Epitope of the Autism-related Bacterium Clostridium bolteae Capsular Octadecasaccharide
Bolteae Clostridium intestinal pathogens have been associated with the onset of autism spectrum disorders (ASD). To make a vaccine against C. bolteae, it is important to identify the appropriate protective epitopes of immunologically active polysaccharide capsule (CPS). Here, we have a set C. bolteae CPS glycans to octadecasaccharide. The key to achieving a total synthesis is the [2 + 2] coupling strategy based on p β-d-Rha – (1 → 3) -α-D-Man p repeat units are in turn accessed via stereoselective β-d -rhamnosylation.
Lock conformation-induced 4,6- O -benzylidene is a powerful strategy to form a β-D-mannose-type glycosides. Indirect strategy is based on the C2 epimerization of the β-D-quinovoside efficiently achieved by Swern oxidation and borohydride reduction. Sequential glycosylation, and global regioselective deprotection produced disaccharide, tetrasaccharide, all the way to octadecasaccharide. Glycan microarray analysis of sera from rabbits immunized with C. bolteae inactive bacteria expressing the humoral immune response to di- and tetrasaccharide but no order anymore. Tetrasaccharide may be the main motive for designing glycoconjugate vaccine against C. bolteae.
Protein glycosylation is modified co- and post-translational, the Leishmania parasite, plays a key role in the interaction of host-parasite vector-vertebrate. In mammalian hosts, Leishmania glycosylation of proteins involved in virulence, host cell invasion, and immune evasion and modulation. The Leishmania glycocalyx composed by dense arrays of glycoconjugates including lipophosphoglycan, glycoinositolphospholipids, glycoproteins and proteophosphoglycans which vary in composition between Leishmania species and stage of development. The current knowledge on the Leishmania protein glycosylation is very limited.
Development of new analytical tools for characterizing and toolbox glycoproteome Leishmania parasite expanding to modulate glycocode will help in solving processes involved in Leishmania-host interactions. This review will be a recapitulation of the current knowledge of Leishmania protein glycosylation and glycan structures were reported, and the potential applications of mass spectrometry-based analysis for the entire system and analysis glycome glycoproteome Leishmania.
Chemical Synthesis Elucidates the Key Antigenic Epitope of the Autism-related Bacterium Clostridium bolteae Capsular Octadecasaccharide
Chemoenzymatic synthesis of arabinomannan (AM) glycoconjugates as potential vaccines for tuberculosis
Mycobacteria infections resulting in tuberculosis (TB) is one of the ten leading causes of death in the world by 2018, and lipoarabinomannan (LAM) has been confirmed to be the most important antigenic polysaccharides on the cell surface TB. In this study, a convenient synthetic methods have been developed to synthesize three branched oligosaccharides derived from LAM, in which a core building block is prepared by enzymatic hydrolysis in the chemical flow with excellent results.
After a few steps from glycosylations, oligosaccharides derived conjugated with recombinant human serum albumin (RHSA) and ex vivo ELISA assays performed using serum obtained from some infected TB patients, to evaluate the affinity of glycoconjugate products for human LAM-antibodies.
Albumin (Human, Mouse, rat, bovine and others) removal kit (synthetic dye based matrix; sufficient to remove 20-40 mg BSA from Bioprocessed material), 2 ml aff column
Albumin (Human, Mouse, rat, bovine and others) removal kit (synthetic dye based matrix; sufficient to remove 50-100 mg BSA from Bioprocessed material), 5 ml aff column
Albumin (Human, Mouse, rat, bovine and others) removal kit (synthetic dye based matrix; sufficient to remove 250-500 mg BSA from Bioprocessed material), 25 ml aff column
Description: Lactacystin is a specific and an irreversible inhibitor of proteasome with IC50 value of 4.8 ?M [1].Lactacystin binds to the catalytic subunits of the 20 S proteasome and inhibits all the three peptidase activities of the proteasome, chymotrypsin-like, trypsin-like and caspase-like.
Description: Lactacystin is a specific and an irreversible inhibitor of proteasome with IC50 value of 4.8 ?M [1].Lactacystin binds to the catalytic subunits of the 20 S proteasome and inhibits all the three peptidase activities of the proteasome, chymotrypsin-like, trypsin-like and caspase-like.
Description: Lactacystin is a specific and an irreversible inhibitor of proteasome with IC50 value of 4.8 ?M [1].Lactacystin binds to the catalytic subunits of the 20 S proteasome and inhibits all the three peptidase activities of the proteasome, chymotrypsin-like, trypsin-like and caspase-like.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Bovine Serum Albumin (BSA) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Bovine Serum Albumin (BSA) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Bovine serum albumin (BSA) removal kit (Antibody based aff matrix; sufficient to remove 1-2 mg BSA from Bioprocessed material), 2 ml aff column
Description: N-Acetylglucosamine-6-Sulfatase is a member of the Sulfatase family. N-Acetylglucosamine-6-Sulfatase is required for the lysosomal degradation of the Glycosaminoglycans (GAG) Heparan Sulfate and Keratan Sulfate. N-Acetylglucosamine-6-Sulfatase hydrolyzes the 6-Sulfate groups of the N-Acetyl-D-Glucosamine 6-Sulfate units of Heparan Sulfate and Keratan Sulfate. N-Acetylglucosamine-6-Sulfatase binds 1 Calcium ion per subunit. N-Acetylglucosamine-6-Sulfatase deficiency are the cause of Mucopolysaccharidosis Type 3D (MPS3D), an inborn error leading to lysosomal accumulation of heparan sulfate. MPS3D has profound mental deterioration, hyperactivity, and relatively mild somatic manifestations.
Description: NAGK Human Recombinant produced in E. coli is a single polypeptide chain containing 367 amino acids (1-344) and having a molecular mass of 39.8kDa.;NAGK is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Human N acetylglucosamine kinase Antibody (Biotin Conjugate)
The evaluation results are positive, especially compound 21 which shows excellent activity that can be considered as the main compound for the future development of new vaccines against TB glycoconjugated.
)
 Conjugate)
-BSA protein Conjugate)
 removal kit (synthetic dye based matrix; sufficient to remove 20-40 mg BSA from Bioprocessed material), 2 ml aff column)
 removal kit (synthetic dye based matrix; sufficient to remove 50-100 mg BSA from Bioprocessed material), 5 ml aff column)
 removal kit (synthetic dye based matrix; sufficient to remove 250-500 mg BSA from Bioprocessed material), 25 ml aff column)
)
)
)
)
)
)
3 peptide (repeat-sequence peptide of the P. berghei circumsporozoite protein, CSP) conjugated with BSA)
3 peptide (repeat-sequence peptide of the P. vivax circumsporozoite protein, CSP) conjugated with BSA)
 pyrophosphoryl-undecaprenol N-acetylglucosamine transferase (murG))
4 peptide (minor repeat-sequence peptide of the P. falciparum circumsporozoite protein, CSP) conjugated with BSA)
5 peptide (25-aa, repeat-sequence peptide of the P. falciparum circumsporozoite protein, CSP) conjugated with BSA)
)
 ELISA Kit)
 removal kit (Antibody based aff matrix; sufficient to remove 1-2 mg BSA from Bioprocessed material), 2 ml aff column)
 removal kit (Antibody based aff matrix; sufficient to remove 10-20 mg BSA from Bioprocessed material), 10 ml aff column)
 removal kit (Antibody based aff matrix; sufficient to remove 25-50 mg BSA from Bioprocessed material), 25 ml aff column)
 Antibody)
 ELISA Kit)
 for ELISA, Western)
 for ELISA , Western)
)
)
)
)
)
, Vaccine adjuvant)
)
 Antibody)
 Antibody)
ELISA Kit)
)
)
)
)